- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03137784
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
January 15, 2019 updated by: Novartis Pharmaceuticals
A Multicenter, Randomized, Double-blind, Placebo-controlled 3-period Complete Cross-over Study to Assess the Bronchodilator Effects and Safety of Glycopyrronium Bromide (NVA237) (25 ug and 50 ug o.d.) in Asthma Patients.
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d.
NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study uses a randomized, double-blind, placebo controlled, 3-period cross-over clinical trial design.
During a screening epoch patient eligibility will be assessed.
The screening epoch will be followed by a 21-day Run-in epoch during which patients will continue their inhaled corticosteroids use but be withdrawn from LABA-treatment and switched to short-acting bronchodilator-rescue medication.
After the Run-in period patients will be randomized to one of the 6 treatment sequences and enter the first 7-day study treatment period.
Treatment period one is followed by a 10 to 14 days washout period after which patients begin the second 7-day treatment period which is then followed by a second 10 to 14 days washout period followed by the third 7-day treatment period.
At the end of each treatment period spirometry will be performed to assess the primary endpoint in terms of trough FEV1.
The study population will consist of approximately 144 patients with asthma who have been treated in a stable regimen of ICS/LABA for at least 4 weeks prior to screening.
Study Type
Interventional
Enrollment (Actual)
148
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Erpent, Belgium, 5100
- Novartis Investigative Site
-
Hasselt, Belgium, 3500
- Novartis Investigative Site
-
Mechelen, Belgium, 2800
- Novartis Investigative Site
-
-
-
-
-
Berlin, Germany, 10119
- Novartis Investigative Site
-
Frankfurt, Germany, 60596
- Novartis Investigative Site
-
Grosshansdorf, Germany, 22927
- Novartis Investigative Site
-
Lubeck, Germany, 23552
- Novartis Investigative Site
-
Wiesbaden, Germany, 65187
- Novartis Investigative Site
-
-
-
-
Tokyo
-
Shinjuku-ku, Tokyo, Japan, 169-0073
- Novartis Investigative Site
-
Toshima-ku, Tokyo, Japan, 171-0014
- Novartis Investigative Site
-
-
-
-
-
Riga, Latvia, LV 1002
- Novartis Investigative Site
-
Riga, Latvia, LV-1038
- Novartis Investigative Site
-
-
LVA
-
Daugavpils, LVA, Latvia, LV-5417
- Novartis Investigative Site
-
-
-
-
-
Klaipeda, Lithuania, LT-92231
- Novartis Investigative Site
-
Klaipeda, Lithuania, LT-92288
- Novartis Investigative Site
-
-
-
-
Massachusetts
-
North Dartmouth, Massachusetts, United States, 02747
- Novartis Investigative Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Novartis Investigative Site
-
-
New Jersey
-
Skillman, New Jersey, United States, 08558
- Novartis Investigative Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Novartis Investigative Site
-
-
Oregon
-
Medford, Oregon, United States, 97504
- Novartis Investigative Site
-
-
Texas
-
El Paso, Texas, United States, 79903
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female adult patients aged >= 18 or =< 65 years
- Patients with a diagnosis of asthma for a period of at least 1 year receiving daily treatment of ICS/LABA in a stable regimen for >= 4 weeks
- Pre-bronchodilator FEV1 of >= 50% and =< 80% of the predicted normal value and an increase in FEV1 of 12% and >= 200 ml during reversibility testing
Key Exclusion Criteria:
- Patients who have had an asthma exacerbation that required either treatment with systemic corticosteroids for at least 3 days, or an emergency room visit, or hospital treatment within 6 weeks prior to screening and patients with a history of life-threatening asthma attacks
- Patients who have had a respiratory tract infection within 4 weeks prior to screening.
- Patients who have smoked or inhaled tobacco products within the past 6 month of screening.
- Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, bronchiectasis, sarcoidosis, interstitial lung disease, cystic fibrosis, and tuberculosis (unless tuberculosis is confirmed as no longer active by imaging).
- Patients on Maintenance Immunotherapy (desensitization) for allergies for at least 3 months prior to Run-in who are expected to change therapy throughout the course of the study.
- Patients who during the Run-in period are shown to be intolerable to LABA withdrawal.
- Patients who have discontinued LAMA therapy in the past (e.g. due to intolerance or perceived lack of efficacy).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1(NVA237 50 ug/NVA237 25 ug/placebo)
Treatment sequence: NVA 237 50 ug, 25 ug and placebo
|
In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
In each treatment arm, patient will receive placebo
|
Other: 2(NVA237 50 ug/placebo/NVA237 25 ug)
Treatment sequence: NVA 237 50 ug, placebo and 25 ug
|
In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
In each treatment arm, patient will receive placebo
|
Other: 3 (NVA237 25 ug/NVA237 50 ug/placebo)
Treatment sequence: NVA237 25 ug, 50 ug and placebo
|
In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
In each treatment arm, patient will receive placebo
|
Other: 4 (NVA237 25 ug/placebo/NVA237 50 ug)
Treatment sequence: NVA 237 25 ug, placebo and 50 ug
|
In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
In each treatment arm, patient will receive placebo
|
Other: 5 (placebo/NVA237 50 ug/ NVA237 25 ug)
Treatment sequence: Placebo, NVA237 50 ug and 25 ug
|
In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
In each treatment arm, patient will receive placebo
|
Other: 6 (placebo/ NVA237 25 ug/NVA237 50 ug)
Treatment sequence: placebo, NVA237 25 ug and 50 ug
|
In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
In each treatment arm, patient will receive placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Trough FEV1 After One Week of Treatment, Point Estimate
Time Frame: Following 1 week of treatment
|
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared to placebo in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post -dose) following 1 week of treatment in the respective treatment period.
Trough FEV1 was assessed by performing spirometry measurements in the clinic for each treatment period.
For the primary efficacy variable, trough FEV1 is the mean of two measurements taken at 23h 15 min and 23h 45 min post dose.
|
Following 1 week of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FEV1 AUC (5 Min-1 h) After One Week of Treatment
Time Frame: Following 1 week of treatment
|
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period.
FEV1 was measured with spirometry conducted according to internationally accepted standards.
The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-1h)
|
Following 1 week of treatment
|
FEV1 AUC (5 Min-4 h) After One Week of Treatment
Time Frame: Following 1 week of treatment
|
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period.
FEV1 was measured with spirometry conducted according to internationally accepted standards.
The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-4h)
|
Following 1 week of treatment
|
FEV1 AUC (5 Min - 23 h 45 Min) After One Week of Treatment
Time Frame: Following 1 week of treatment
|
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period.
FEV1 was measured with spirometry conducted according to internationally accepted standards.
The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day AUC (5 min - 23 h 45 min)
|
Following 1 week of treatment
|
Peak FEV1 During 4 Hours Post-dose After 1 Week of Treatment
Time Frame: Following 1 week of treatment
|
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Peak FEV1 following 1 week of treatment in the respective treatment period.
FEV1 was measured with spirometry conducted according to internationally accepted standards.
The peak effect following 1 week of treatment was defined as the maximum FEV1 during the first 4 hour on that day.
|
Following 1 week of treatment
|
Trough Forced Vital Capacity (FVC) After 1 Week of Treatment
Time Frame: Following 1 week of treatment
|
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FVC following 1 week of treatment in respective treatment period.
Trough Forced Vital Capacity (FVC) following 7 Days.
FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
FVC was assessed via spirometry
|
Following 1 week of treatment
|
Percent Change From Baseline in FEV1/FVC Ratio
Time Frame: Following 1 week of treatment
|
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FEV1/FVC ratio following 1 week of treatment in respective treatment period
|
Following 1 week of treatment
|
Mean Morning Peak Expiratory Flow (PEF) Following the 1-week Treatment Period
Time Frame: Following 1 week of treatment
|
A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed.
During the Screening and Treatment Periods, PEF was measured in the morning and evening every day.
the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later.
Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication.
The highest of 3 values was recorded as the daily personal best.
The personal best was used to calculate the mean morning PEF and mean evening PEF value
|
Following 1 week of treatment
|
Mean Evening Peak Expiratory Flow Rate (PEF) Following 1-week Treatment
Time Frame: Following 1 week of treatment
|
A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed.
During the Screening and Treatment Periods, PEF was measured in the morning and evening every day.
the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later.
Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication.
The highest of 3 values was recorded as the daily personal best.
The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits.
LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates
|
Following 1 week of treatment
|
Mean Daily Number of Puffs of Rescue Medication During 1 Week of Treatment
Time Frame: Following 1 week of treatment
|
A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours.
daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs.
|
Following 1 week of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 4, 2017
Primary Completion (Actual)
December 29, 2017
Study Completion (Actual)
December 29, 2017
Study Registration Dates
First Submitted
April 24, 2017
First Submitted That Met QC Criteria
April 28, 2017
First Posted (Actual)
May 3, 2017
Study Record Updates
Last Update Posted (Actual)
January 16, 2019
Last Update Submitted That Met QC Criteria
January 15, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Anticonvulsants
- Glycopyrrolate
- Bromides
Other Study ID Numbers
- CQVM149B2204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on NVA237 (glycopyrronium bromide)
-
Novartis PharmaceuticalsRecruitingAsthmaSpain, Hungary, United Kingdom, South Africa, Colombia, Bulgaria, Poland, Guatemala
-
NovartisCompletedChronic Obstructive Pulmonary Disease (COPD)United States, Spain, Turkey, France, Netherlands, Germany
-
NovartisCompletedChronic Obstructive Pulmonary DiseaseUnited States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
-
Novartis PharmaceuticalsCompletedCOPDGermany, Belgium, Poland, Romania, Italy, Spain, Estonia, Russian Federation, Austria, France, Slovakia, Czechia, Latvia, Lithuania, Greece, Hungary, United Kingdom, Portugal, Ireland, Norway, Slovenia, Denmark, Sweden
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseUnited States, Germany, Hungary, Belgium, Poland, Spain, Netherlands
-
University of SaskatchewanCompleted
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingChronic Obstructive Pulmonary DiseaseChina
-
Prosonix LimitedCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom